Mindray Bc-10 Auto 3-Diff Poct 30 Tests/Hour Blood Cell Counter Hematology Analyzer

Name: Mindray Bc-10 Auto 3-Diff Poct 30 Tests/Hour Blood Cell Counter Hematology Analyzer
Brand: Guangzhou Sunnymed Limited
SKU: 1953572701

Guangdong, ChinaGuangzhou Sunnymed Limited

US$200.00-2,499.00

1 Set

Product profile

Customization

Available

Product Name

Auto Hematology Analyzer

Model

Mindray Bc-10

Model NO.

Mindray BC-10

Feature

Cbc+3-Diff, 20 Parameters+3histograms

Test Speed

30 Test/H

Keyboard

Dimension

410*300*400mm

Weight

20kg

Reagents

Only 3 Reagents Needed

Trademark

Sunnymed

Origin

Guangzhou, China

Company profile

Importers and ExportersHigh Repeat Buyers ChoiceQuality Assurance

Guangzhou Sunnymed Limited

Guangdong, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service Available CertifiedCustomization Options: Customization from Samples, Customization from Designs, etc. CertifiedExport Year: 5 years CertifiedNearest Port: Guangzhou PortAverage Response Time: ≤6.81h

AI-Powered supplier vetting

SummaryThe supplier demonstrates broad customization, OEM and ODM capabilities, documented finished-product inspection, quality assurance, raw-material traceability, and five production lines. It reports recent product development, 11–20 quality-control staff, four experienced export-trade staff, and an off-season lead time within 15 workdays. The supplier also cites deliveries of medical equipment and consumables to hospitals in Zambia, Qatar, and Bangladesh. However, important operational weaknesses are documented: no written procedures or records for service-capability assessment, corrective and preventive actions, or complaint handling; no approved service-supplier list; no ongoing batch quantity reconciliation; and no overseas warehouse, showroom, agents, branches, or offline trade-show participation. Certification holdings are not provided, and financial figures and sustainability-control statuses are insufficiently evidenced for a definitive assessment.

Supplier typeThe supplier’s stated business scope includes supplying and wholesaling medical protective equipment, information consulting, software outsourcing and sales, and internet sales. Its profile also describes medical-equipment and consumables deliveries, indicating a supplier with both trading and product-delivery activities rather than a clearly defined single manufacturing-only type.

After-Sales capabilityThe supplier has instructions that are uniformly followed for finished-product inspection and maintains quality-control records, quality assurance, raw-material traceability, and work-instruction procedures. However, it reports no written procedures or records for handling customer complaints, no written service-capability assessment or corrective/preventive-action records, and no overseas warehouse, showroom, agents, branches, or offline trade-show experience.

R&D capabilityThe supplier reports new products within the past year, ODM services, and flexible design support, while its R&D engineers have two years of total experience. It does not provide an available SDK, so its demonstrated innovation capability is present but not complete across the stated criteria.

Production capacityThe supplier operates five production lines, has 11–20 quality-control staff, maintains quality-assurance and traceability practices, and reports an off-season lead time within 15 workdays. However, it does not conduct ongoing quantity reconciliation for each batch or production lot, which is a documented production-control weakness.

Customization capabilityThe supplier explicitly offers flexible, minor, and full customization, including customization from designs and samples, and provides ODM services. It also reports OEM service for well-known brands, although no SDK is available.

Client casesThe company description states that SUNNYMED delivered thousands of medical equipment units and related consumables to hospitals in Zambia, a Qatar government hospital, and Bangladesh government hospitals within two months. This provides specific international institutional delivery evidence, although no customer names, dates, contracts, or independent verification are supplied.